Weekly Spotlight - 31.10.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Nipocalimab Shows Promise in Treating Generalised Myasthenia Gravis

Nipocalimab, a novel treatment for myasthenia gravis, demonstrates potential in reducing disease severity. Unlike its cyclical counterparts, it offers a consistent treatment regimen every two weeks. While early results are promising, the long-term effects are yet to be determined. This medication adds to the growing arsenal of therapies available for managing myasthenia gravis.

Inebilizumab Shows Promise in Myasthenia Gravis Treatment Trial

Inebilizumab has shown significant promise in treating myasthenia gravis, according to Amgen's phase 3 clinical trial, which involved 238 patients. The trial highlighted both the efficacy and safety of the treatment, particularly among individuals with specific antibodies. While the initial results are encouraging, further analysis is warranted. We will continue to monitor developments in this important area of research.

Digital Tool Assesses Steroid Toxicity in Myasthenia Gravis Patients

A new digital tool has been introduced to assess steroid toxicity in patients with myasthenia gravis. The Glucocorticoid Toxicity Index-Metabolic Domains (GTI-MD) utilizes electronic health records to facilitate early detection of toxicity. This innovative approach aids clinicians in balancing steroid use with overall patient well-being.

Understanding Speech Issues in Myasthenia Gravis

MG can result in speech difficulties due to muscle weakness, which may impact both verbal communication and swallowing. Common symptoms include hoarseness, slurred speech, and vocal fatigue. Interventions such as thymectomy and pharmacotherapy can effectively manage these symptoms. If speech issues persist, it is important to consult a healthcare provider, as MG may be the underlying cause.